Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 3/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 5/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6023156 | 0.97 | USP2 (0.42) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL6022956 | 0.91 | SPHK1 (0.38) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL6023970 | 0.91 | GRIN2B (0.40) | USP2ALDH1A1MAPTIGF1RKMT2A | |
| SCHEMBL6023503 | 0.91 | KDM4E (0.39) | IGF1RKMT2ASPHK1HRH1DRD2 | |
| SCHEMBL6022920 | 0.91 | KDM4E (0.39) | IGF1RKMT2ASPHK1HRH1DRD2 | |
| SCHEMBL6023543 | 0.90 | KMT2A (0.40) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL6023884 | 0.90 | SPHK1 (0.41) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL6023116 | 0.89 | SPHK1 (0.41) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL6022899 | 0.89 | SPHK1 (0.40) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL6023325 | 0.89 | SPHK1 (0.40) | MAPTIGF1RSPHK1HRH1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078407-B2 | 4-hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2006-07-18 | — | — | US | claimed |
| US-20030162789-A1 | 4-Hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2003-08-28 | — | — | US | claimed |
| US-7078407-B2 | 4-hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2006-07-18 | — | — | US | disclosed |
| US-20030162789-A1 | 4-Hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162789-A1 | 4-Hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them | HTT, PARK7, NQO1 | ADRB2 2452/4885ADRB1 2173/4885ADRB3 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.